Table 3 Survival times and progression times between cTACE and DEB-TACE treatments

Total

(n = 201)

(n = 72)

 Survival status

  Died within ≤5 years follow-up

153 (76.1)

48 (66.7)

  Died after more than 5 years follow-up

10 (5.0)

1 (1.4)

  Survived until last follow-up

38 (18.9)

23 (31.9)

 Progression status

  Progression

192 (95.5)

66 (91.7)

  Loss of follow-up/censored

9 (4.5)

6 (8.3)

 Survival time, months

37 (32.2, 41.8)

37 (23.5, 50.5)

 Progression time, months

11.0 (9.6, 12.4)

16.0 (13.1, 18.9)

BCLC stage = A

(n = 73)

(n = 16)

 Survival status

  Died within ≤5 years follow-up

57 (78.1)

9 (56.3)

  Died after more than 5 years follow-up

3 (4.1)

0 (0)

  Survived until last follow-up

13 (17.8)

7 (43.8)

 Progression status

  Progression

70 (95.9)

14 (87.5)

  Loss of follow-up/censored

3 (4.1)

2 (12.5)

 Survival time, months

42 (36.1, 47.9)

45 (0, 90.1)

 Progression time, months

12 (10.5, 13.5)

19 (17.8, 20.2)

BCLC stage = B + C

(n = 128)

(n = 56)

 Survival status

  Died within ≤5 years follow-up

96 (75)

39 (69.6)

  Died after more than 5 years follow-up

7 (5.5)

1 (1.8)

  Survived until last follow-up

25 (19.5)

16 (28.6)

 Progression status

  Progression

122 (95.3)

52 (92.9)

  Loss of follow-up/censored

6 (4.7)

4 (7.1)

 Survival time, months

33 (27.1, 38.9)

36 (21.3, 50.7)

 Progression time, months

10 (8.1, 11.9)

15 (12.4, 17.7)